ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

9480	Companies
185559	Keywords
117951	Articles
99390	Press releases

Home
Companies
ABIVAX

BRIEF

published on 07/24/2025 at 07:35, 4 months 12 days ago

Abivax suspend temporairement sa cotation sur Euronext Paris

Euronext Paris Biotechnologie Abivax Offre Publique Suspension Des Échanges
BRIEF

published on 07/24/2025 at 07:35, 4 months 12 days ago

Abivax Temporarily Halts Trading on Euronext Paris

Euronext Paris Biotechnology Abivax Trading Halt Public Offering
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 12 days ago

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Suspension Temporaire
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 12 days ago

Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris. La suspension intervient dans le cadre de l'Offre d'American Depositary Shares

Euronext Paris Biotechnologie Abivax Offre Publique Suspension Temporaire
PRESS RELEASE

published on 07/24/2025 at 07:30, 4 months 12 days ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris due to public offering preparations

Euronext Paris Abivax Trading Halt Public Offering Clinical-stage Biotechnology
BRIEF

published on 07/23/2025 at 22:20, 4 months 13 days ago

Abivax Launches $400 Million Public Offering

Ulcerative Colitis Clinical Development Capital Market Abivax Public Offering Biotechnology Financing
BRIEF

published on 07/23/2025 at 22:20, 4 months 13 days ago

Abivax lance une offre publique de 400 millions de dollars

Développement Clinique Rectocolite Hémorragique Marché Des Capitaux Offre Publique D'Abivax Financement De La Biotechnologie
PRESS RELEASE

published on 07/23/2025 at 22:15, 4 months 13 days ago

Abivax annonce le lancement d’une offre au public
Abivax lance une offre publique d'environ 400 millions de dollars, émise sur le Nasdaq et Euronext, pour financer le développement de thérapies biotechnologiques

Euronext Biotechnologie Abivax Nasdaq Offre Publique
PRESS RELEASE

published on 07/23/2025 at 22:15, 4 months 13 days ago

Abivax annonce le lancement d’une offre au public
Abivax lance une offre publique de 400 millions de dollars pour le développement de thérapies en biotechnologie. ADS négociées sur Nasdaq et Actions Ordinaires sur Euronext

Euronext Biotechnologie Abivax Ads Offre Publique
PRESS RELEASE

published on 07/23/2025 at 22:15, 4 months 13 days ago

Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers

Biotechnology Financing Abivax Underwriters Public Offering

Accesswire

Published on 12/05/2025 at 21:45, 1 hour 5 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 1 hour 20 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 30 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 50 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 25 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 34 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 38 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 52 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 4 hours 23 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 4 hours 34 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 32 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 39 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 51 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE